• 1  Palamaras I, Kyriakis KP, Stavrianeas NG. Seborrhoeic dermatitis: lifetime detection rates. J Eur Acad Dermatol Venereol 2012;26:524–6. Cross Ref link Pubmed link
  • 2  Turner GA, Hoptroff M, Harding CR. Stratum corneum dysfunction in dandruff. Int J Cosmet Sci 2012;34:298–306. Cross Ref link Pubmed link
  • 3  Johnson ML, Roberts J. Skin conditions and related need for medical care among persons 1–74 years, United States 1971–1974. Vital Health Stat 1978:11. US Department of Health, Education and Welfare.
  • 4  Kim TG, Lee KH, Oh SH. Skin disorders in Korean patients infected with human immunodeficiency virus and their association with a CD4 lymphocyte count: a preliminary study. J Eur Acad Dermatol Venereol 2010;24:1476–80. Cross Ref link Pubmed link
  • 5  De Moraes, AP, de Arruda EA, Vitoriano MA, et al. An open label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. Eur Acad Dermatol Venereol 2007;21:596–601.
  • 6  Dantas L, Netto E, Glesby MK, Carvalho EM, Machado P. Dermatological manifestations of individuals infected with human T cell lymphotrophic virus type 1 (HTLV1). Int J Dermatol 2014;53:1098–102. Cross Ref link Pubmed link
  • 7  Lally A, Casabonne D, Newton R, Wojnarowska F. Seborrhoeic dermatitis among Oxford renal transplant recipients. J Eur Acad Dermatol Venereol 2010;24:561–4. Cross Ref link Pubmed link
  • 8  Binder RL, Jonelis FJ. Seborrhoeic dermatitis in neuroleptic induced Parkinsonism. Arch Dermatol 1983;119:473–5. Cross Ref link Pubmed link
  • 9  Han ZA, Choi JY, Ko YJ. Dermatological problems following spinal cord injury in Korean patients. J Spinal Cord Med 2013;24, epub ahead of print.
  • 10  Malassez L. Note sur le champignon du pityriasis simple. Arch Physiol 1874;1:451–9.
  • 11  Hay R. Malassezia, dandruff and seborrhoeic dermatitis: an overview. Br J Dermatol 2011;165(Suppl. 2):2–8. Cross Ref link Pubmed link
  • 12  Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984;111:235–42. Cross Ref link Pubmed link
  • 13  Tajima M, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol 2008;128:345–51. Cross Ref link Pubmed link
  • 14  Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeast: facts and controversies. Clin Dermatol 2013;31:455–63. Cross Ref link Pubmed link
  • 15  Patino‐Uzcategui A, Amando Y, Cepero de Garcia M, et al. Virulence gene expression in Malassezia spp from individuals with seborrheic dermatitis. J Invest Dermatol 2011;131:2134–6. Cross Ref link Pubmed link
  • 16  Dawson TL. Malassezia globosa and restricta: breakthrough understanding of the aetiology and treatment of dandruff and seborrheic dermatitis through whole genome analysis. J Invest Dermatol Symp Proc 2007;12:15–19. Cross Ref link
  • 17  Gaitanis G, Magiatis P, Stathoupoulou K, et al. AhR ligands, malassezin and indolo[3,2‐b]carbazole are selectively produced by Malassezia furfur strains isolated from seborrheic dermatitis. J Invest Dermatol 2008;128:1620–5. Cross Ref link Pubmed link
  • 18  Vlachos C, Schulte BM, Magiatis P, Adema GJ, Gaitanis G. Malassezia‐derived indoles activate the aryl hydrocarbon receptor and inhibit toll‐like receptor‐induced maturation in monocyte‐derived dendritic cells. Br J Dermatol 2012;167:496–505. Cross Ref link Pubmed link
  • 19  Emre S, Metin A, Demirseren DD, et al. The association of oxidative stress and disease activity in seborrhoeic dermatitis. Arch Dermatol Res 2012;304:683–7. Cross Ref link Pubmed link
  • 20  Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012;25:106–41. Cross Ref link Pubmed link
  • 21  Thomas DS, Ingham E, Bojar RA, et al. In vitro modulation of human keratinocyte pro‐and anti‐inflammatory cytokine production by the capsule of Malassezia species. FEMS Immunol Med Microbiol 2008;54:203–14. Cross Ref link Pubmed link
  • 22  Viode C, Lejeune O, Trulier V, et al. Cathepsin S, a new pruritus biomarker in clinical dandruff/seborrhoeic dermatitis evaluation. Exp Dermatol 2014;23:274–5. Cross Ref link Pubmed link
  • 23  Kerr K, Schwartz JR, Filoon T, et al. Scalp stratum corneum histamine levels: novel sampling method reveals association with itch resolution in dandruff/seborrhoeic dermatitis treatment. Acta Derm Venereol 2011;91:404–8. Cross Ref link Pubmed link
  • 24  Ercis M, Balci S, Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit. Clin Genet 1996;50:317–20. Pubmed link
  • 25  Birnbaum RY, Zvulunov A, Hallel‐Halevy D, et al. Seborrhea‐like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. Nat Genet 2006;38:749–51. Cross Ref link Pubmed link
  • 26  Ramos‐e‐Silva M, Sampaio AL, Carneiro S. Red face revisited: endogenous dermatitis in the form of atopic dermatitis and seborrhoeic dermatitis. Clin Dermatol 2014;32:109–15. Cross Ref link Pubmed link
  • 27  Berg M. Epidemiological studies on the influence of sunlight on the skin. Photodermatology 1989;6:80–4. Pubmed link
  • 28  Moehrie M, Dennemoser B, Schlagenjauff B, Thomma S, Garbe C. High prevalence of seborrhoeic dermatitis on the face and scalp of mountain guides. Dermatology 2000;210:146–7. Cross Ref link
  • 29  High WA, Pandaya AG. Pilot trial of 1% pimecrolmus cream in the treatment of seborrhoeic dermatitis in African American adults with associated hypopigmentation. J Am Acad Derm 2006;54:1083–8 Cross Ref link Pubmed link
  • 30  Wolf R, Orion E, Tuzun Y. Periorbital (eyelid) dermatitides. Clin Dermatol 2014;32:131–40. Cross Ref link Pubmed link
  • 31  Berth‐Jones J. Seborrhoeic dermatitis. In: Burns DA, Breathnach SM, Cox N, Griffiths C, eds. Rook's Textbook of Dermatology, 8th edn. Oxford: Blackwell Publishing, 2010:23.29–23.42.
  • 32  Crone AM, Stewart EJ, Wojnarowska F, Powell SM. Aetiological factors in vulvar dermatitis. J Eur Acad Dermatol Venereol 2000;14:181–6. Cross Ref link Pubmed link
  • 33  Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology 2004;208:89–93. Cross Ref link Pubmed link
  • 34  Alexopoulos A, Kakourou T, Orfanou I, Xaidara A, Chrousos G. Retrospective analysis of the relationship between infantile seborrhoeic dermatitis and atopic dermatitis. Pediatr Dermatol 2014;31(2):125–30. Cross Ref link Pubmed link
  • 35  Kitamura K, Aihara M, Osawa J, Naito S, Ikezawa Z. Sulfhydryl drug‐induced eruption: a clinical and histological study. J Dermatol 1990;17:44–51. Cross Ref link Pubmed link
  • 36  Tavakoli‐Tabasi S, Bagree A. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and rivbavirin treatment of hepatitis C. J Clin Gastroenterol 2012;46:162–7. Cross Ref link Pubmed link
  • 37  Kawakami Y, Nakamura‐Wakatsuki T, Yamamoto T. Seborrheic dermatitis‐like eruption following interlukin‐2 administration. Dermatol Online J 2010;16:12. Pubmed link
  • 38  Yamamoto T, Suboi R. Interleukin‐2‐induced seborrheic dermatitis‐like eruption. J Eur Acad Dermatol Venereol 2008;22:244–5. Pubmed link
  • 39  Cork MK, Keohane SG, Gawkrodger DJ, Hancock BW, Sheridan E, Bleehen S.S Cytokine dermatosis: reactivation of eczema during interleukin‐2 infusion. Br J Dermatol 1997;136(4):644–5. Cross Ref link Pubmed link
  • 40  Pitarch G, Gards J, Torrijos A, Juarez A, Febrer MI, Camps C. Adverse cutaneous reactions to erlotinib. Actas Dermosifilogr 2008;99(1):54–60. Cross Ref link
  • 41  Benomar S, Boutayeb S, Afifi Y, et al. Hand–foot syndrome and seborrheic dermatitis like eruption induced by erlotinib. Dermatol Online J 2009;15:2. Pubmed link
  • 42  Yang CH, Lin WC, Chuang CK, et al. Hand–foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158(3):592–6. Cross Ref link Pubmed link
  • 43  Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW. Hand–foot syndrome and seborrhoeic dermatitis‐like rash induced by sunitinib. J Clin Oncol 2006;24(36):5786–8. Cross Ref link Pubmed link
  • 44  Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012;148(5):628–33. Cross Ref link Pubmed link
  • 45  Comert A, Bekirolgu N, Gurbuz O, Ergun T. Efficacy of oral fluconazole in the treatment of seborrheic dermatitis. Am J Clin Dermatol 2007;8:253–8.
  • 46  Chatzikokkinou P, Sotiropoulos K, Katoulis A, Luzzati R, Trevisan G. Seborrhoeic dermatitis – an early and common skin manifestation in HIV patients. Acta Dermatovenereol Croat 2008;16(4):226–30.
  • 47  Scognamiglio P, Chiaradia G, DeCarli G, et al. The potential impact of routine testing of individuals with HIV disease in order to prevent late HIV diagnosis. BMC Infect Dis 2013;13:473. Cross Ref link Pubmed link
  • 48  Sullivan AK, Raben D, Reekie J, et al. Feasibility and effectiveness of indicator‐condition guided testing for HIV: results from HIDES 1 (HIV Indicator Disease across Europe Study). PLOS One 2013;8:e52845. Cross Ref link Pubmed link
  • 49  Osei‐Sekyere B, Karstaedt AS. Immune reconstitution inflammatory syndrome involving the skin. Clin Exp Dermatol 2010;35(5):477–81. Cross Ref link Pubmed link
  • 50  Misery L, Touboul S, Vincot C, et al. Stress and seborrhoeic dermatitis. Ann Dermatol Venereol 2007;134:833–7. Cross Ref link Pubmed link
  • 51  Peyri J, Lleonart M, Grupo Espanol del Estudio SEBDERM. Clinical and therapeutic profile and quality of life of patients with seborrhoeic dermatitis. Actas Dermosifilogr 2007;98:476–82. Cross Ref link
  • 52  Maietta G, Fornaro P, Rongioletti F, Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol 1990;70(5):432–4. Pubmed link
  • 53  Comert A, Akbas B, Kilic EZ, et al. Psychatric comorbidities and alexithymia in patients with seborrheic dermatitis: a questionnaire study in Turkey. Am J Clin Dermatol 2013;14:335–42. Cross Ref link Pubmed link
  • 54  Strumia R. Skin signs in anorexia nervosa. Dermatoendocrinology 2009;1:268–70. Cross Ref link
  • 55  Parish LC, Fine E. Alcoholism and skin disease. Int J Dermatol 1985;24:300–1. Cross Ref link Pubmed link
  • 56  Mastrolonardo M, Diaferio A, Vendemiale G, Lopalco P. Seborrhoeic dermatitis in the elderly: inferences on the possible role of disability and loss of self‐sufficiency. Acta Derm Venereol 2004;84:285–7. Cross Ref link Pubmed link
  • 57  Linder D, Dreiher J, Zampetti A, Sampogna F, Cohen AD. Seborrheic dermatitis and hypertension in adults: a cross‐sectional study. Eur Acad Dermatol Venereol 2014;28:1450–5. Cross Ref link
  • 58  Breunig JA, de Almeida JL, Druiga RP, Souza PR, Staub HL. Scalp seborrhoeic dermatitis: prevalence and associated factors in male adolescents. Int J Dermatol 2012;51:46–9. Cross Ref link Pubmed link
  • 59  Peyri L, Lleonart M, Grupo Espanol del Studio SEBDERM. Clinical and therapeutic profile and quality of life of patients with seborrhoeic dermatitis. Acta Dermatosifilogr 2007;98:476–82. Cross Ref link
  • 60  Prinsen CA, Lindeboon R, de Korte J. Interpretation of Skindex‐29 scores; cut offs for mild, moderate and severe impairment of Health‐Related Quality of Life. J Invest Dermatol 2011;113:1945–7. Cross Ref link
  • 61  Kim GW, Jung HJ, Ko HC, et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrhoeic dermatitis. Br J Dermatol 2011;164:652–6. Pubmed link
  • 62  Civatte A. Psoriasis and seborrheic eczema: pathological anatomy and diagnostic histology of the two dermatoses. Br J Derm Syph 1924;36:461. Cross Ref link
  • 63  Pinkus H, Mehregan AH. The primary histologic lesion of seborrhoeic dermatitis and psoriasis. J Invest Dermatol 1966;46:109–16. Cross Ref link Pubmed link
  • 64  Emtestam L, Svensoon A, Rensfeldt K. Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid and propylene glycol (k301): results of two double‐blind, randomized, placebo‐controlled studies. Mycoses 2012;55:393–403. Cross Ref link Pubmed link
  • 65  Elewski BE, Cantrell WC. An open‐label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrhoeic dermatitis. J Drugs Dermatol 2011;10:895–9. Pubmed link
  • 66  Draelos ZD, Feldman SR, Butner V, AlioSaenz AB. Long‐term safety of ketoconazole foam 2% in the treatment of seborrhoeic dermatitis: results of a phase IV open‐label study. J Drugs Dermatol 2013;12:e1–6. Pubmed link
  • 67  Nakamura A, Kano A, Murai T, et al. Susceptibility testing of Malassezia species using the urea broth microdilution method. Antimicrob Agents Chemother 2000;44:2185–6. Cross Ref link Pubmed link
  • 68  Azimi H, Golforoushan F, Jaberian M, Talghini S, Goldust M. Efficiency of terbinafine 1% cream in comparison with ketoconazole 2% cream and placebo in patients with facial seborrhoeic dermatitis. J Dermatolog Treat 2013:June 6, epub. Pubmed link
  • 69  Gold MH, Bridges T, Avakian EV, Plaum S, Fleischer AB, Hardas B. An open‐label study of naftifine 1% gel in the treatment of seborrhoeic dermatitis of the scalp. J Drugs Dermatol 2012;11:514–18. Pubmed link
  • 70  Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat 2007;18:88–96. Cross Ref link Pubmed link
  • 71  Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors and treatments: facts and controversies. Clin Dermatol 2013;31:343–51. Cross Ref link Pubmed link
  • 72  Dreno B, Chosidow O, Revuz J, Moyse D, Study Investigator Group. Lithium 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre randomized study. Br J Dermatol 2003;186:1230–6. Cross Ref link
  • 73  Ballanger D, Tenaud I, Volteau C, Khammari A, Dreno B. Anti‐inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res 2008;300:215–23. Cross Ref link Pubmed link
  • 74  Fabrocini G, Cantelli M, MOnfrecola G. Topical nicotinamide for seborreic dermatitis: an open randomized study. J Dermatolog Treat 2014;25:241–5 Cross Ref link Pubmed link
  • 75  Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat 2009;20:344–9. t Cross Ref link Pubmed link
  • 76  Kwon SH, Jeong MY, Park KC, Youn SW, Huh CH, Na JI. A new therapeutic option for facial seborrhoeic dermatitis: indole‐3‐acetic acid photodynamic therapy. J Eur Acad Dermatol Venereol 2014;28:94–9. Cross Ref link Pubmed link
  • 77  Jang MS, Doh KS, Kang JS, Jeon YS, Suh KS, Kim ST. A comparative split‐face study of photodynamic therapy with lindocyanine green and indole‐3‐acetic acid in the treatment of acne vulgaris. Br J Dermatol 2011;165:1095–100. Cross Ref link Pubmed link
  • 78  Wananukul S, Chatproedprai S, Charutragulachai W. Randomized double‐blind, split‐side comparison study of moisturizer containing lichochalcone vs. 1% hydrocortisone in the treatment of infantile seborrhoeic dermatitis. J Eur Acad Dermatol 2012;26:894–7 Cross Ref link
  • 79  Ortonne JP, Nikkels AF, Reich K, et al. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Br J Dermatol 2011;165:171–6. Cross Ref link Pubmed link
  • 80  National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. cks.nice.org.uk/seborrhoeic‐dermatitis (last accessed January 2015).
  • 81  Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrhoeic dermatitis: a review of pathophysiology, safety and efficacy. Am J Clin Dermatol 2009;10:103–18. Cross Ref link Pubmed link
  • 82  Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double‐blind, vehicle‐controlled, multi‐centre trial. Acta Derm Venereol 2013;93:557–61 Cross Ref link Pubmed link
  • 83  Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venerol 2014;28:16–26. Cross Ref link
  • 84  Pirkhammer D, Seeber A, Honiggmann H, Tanew A. Narrow‐band ultraviolet B (ATL‐01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000;143:964–8. Cross Ref link Pubmed link
  • 85  Ryu S, Choi SY, Acharya S, et al. Antimicrobial and anti‐inflammatory effects of cecropinA(1‐8)‐Magainin2(1‐12) hybrid peptide analog P5 against Malassezia furfur infection in human keratinocytes. J Invest Dermatol 2011;131:1677–83. Cross Ref link Pubmed link